ERBB2 and breast carcinoma: A high-throughput screening of 1626 miRNA mimics and inhibitors in combination with trastuzumab and lapatinib was conducted in HER2+ breast cancer cells to determine whether miRNAs could render HER2+ cells more sensitive to the treatment.